Introduction
T r o v a floxacin is an investigational triflu o r o n a p h t h y r i d o n e with a different structure from quinolones such as norfloxacin and ciproflo x a c i n . 1 It contains a C-7 ring moiety (3-azabicyclo[3.1.0]hexyl) on a basic naphthyridone configuration. The difluorinated 1-N substitution of trovaflo x a c i n is identical to that of tosufloxacin, and produces enhanced activity against some ciprofloxacin-resistant organisms. T r o v a floxacin possesses a broad antimicrobial spectrum against Gram-positive and Gram-negative bacterial isolates including ciprofloxacin-resistant isolates. 1 , 2 It also has substantial activity against clinically significant groups of anaerobic organisms and against Neisseria gonorrhoeae.
3 , 4 T h e quinolones (norfloxacin, ciprofloxacin, ofloxacin) have been used both for prophylaxis against infection and for the treatment of febrile episodes in neutropenic cancer patients. 5 , 6 I n this study we compared the in-vitro activity of trovaflo x a c i n with that of norfloxacin, ofloxacin and ciprofloxacin, which are currently available for clinical use in the USA, and to l e v o floxacin and sparfloxacin, which are still under investigation, against clinical isolates from cancer patients.
Materials and methods
Trovafloxacin was provided by Pfizer Central Research (Groton, CT, USA). The standard powders of ciprofloxacin, norfloxacin, ofloxacin, levofloxacin and sparfloxacin were provided by their respective domestic manufacturers. These were kept frozen at 70°C until use.
A total of 716 organisms were tested. All organisms were isolated from patients admitted to The University of Texas M. D. Anderson Cancer Center at Houston during the past 5 years. Most ( 90%) of these isolates were from blood culture specimens; and the rest were from various clinical sources including sputum, urine, wounds, bile and cerebrospinal fluid. Many isolates came from patients who had received penicillins, cepholosporins, monobactams, carbapenems, aminoglycosides and quinolones for therapy or prophylaxis. Only one isolate per patient was used for testing in order to avoid duplication. Staphylococcus aureus and Staphylococcus epidermidis isolates were considered to be penicillin-susceptible on the basis of an MIC of 0.1 mg/L, methicillin-susceptible on the basis of an MIC of 4.0 mg/L and methicillin-resistant on the basis of an MIC of 8.0 mg/L.
Susceptibility testing was performed using a microtitre, broth-dilution method which is in accordance with guidelines established by the National Committee for Clinical Laboratory Standards. 7 Briefly, organisms were inoculated into broth and were incubated overnight at 37°C. Appropriate dilutions were then made so that the final inoculum tested was 5 10 5 cfu/mL. The test medium used was cation-adjusted Mueller-Hinton broth (Difco Labora-The antibacterial activity of trovafloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin, sparfloxacin and norfloxacin against bacterial isolates from patients with cancer. In general, the activity of trovafloxacin was comparable to that of ciprofloxacin, levofloxacin and sparfloxacin against most Gram-negative isolates tested (minor differences in the activity of each agent against individual species were seen) and it was the most active agent tested against Stenotrophomonas maltophilia, inhibiting 80% of these isolates at ≤2.0 mg/L. Trovafloxacin was also the most active agent tested against Gram-positive organisms, including ciprofloxacin-susceptible strains and most ciprofloxacin-and methicillin-resistant staphylococci and enterococci. It was much more active than ciprofloxacin against streptococci, including Streptococcus pneumoniae and the viridans streptococci, and was also active against Bacillus cereus and Listeria monocytogenes, inhibiting all isolates at a concentration of ≤0.5 mg/L. tories, Detroit, MI, USA) for all organisms except Corynebacterium jeikeium, which were tested in brain heart infusion broth with 5% rabbit serum, and the streptococci, which were tested in cation-adjusted MuellerHinton broth with 2% lysed horse blood. Antibiotic concentrations were prepared manually with serial twofold dilutions ranging from 64 to 0.03 mg/L, and were dispersed automatically with an MIC-2000 apparatus (Dynatech Laboratories, Inc., Alexandria, VA, USA). S. aureus ATCC 25933, Escherichia coli ATCC 25992 and Pseudomonas aeruginosa ATCC 27853 were used as control strains to validate the results. The MIC was defined as the lowest concentration of each antimicrobial agent that inhibited visible growth after 16-20 h of incubation at 35°C.
Results
The overall susceptibility results are shown in the and Serratia marcescens at a concentration of 0.25 mg/L. Trovafloxacin was also active against Enterobacter cloacae and Pseudomonas putida inhibiting 90% or more of these isolates at a concentration of 1 mg/L. Trovafloxacin inhibited 78% of P. aeruginosa isolates at a concentration of 2 mg/L, and had better activity than any of the other agents tested against Stenotrophomonas maltophilia, inhibiting 80% of these isolates at 2 mg/L. Alcaligenes denitrificans subsp. xylosoxidans isolates were relatively resistant with an MIC range of 8.0-16.0 mg/L. Other organisms for which trovafloxacin MICs were 4 mg/L were rare (P. aeruginosa, S. maltophilia and one isolate each of Acinetobacter sp., Citrobacter freundii, E. coli and S. marcescens). In general, the activity of trovafloxacin was comparable to that of ciprofloxacin, sparfloxacin and levofloxacin against the majority of Gram-negative isolates tested, although minor differences in the activity of each agent were seen against individual species. The activity of ofloxacin and norfloxacin was two-to 32-fold less than that of trovafloxacin for most isolates tested.
Trovafloxacin was the most active of the agents tested against Gram-positive isolates, including methicillin-and ciprofloxacin-resistant strains. Against ciprofloxacinsusceptible strains of staphylococci, the MIC 90 was 0.06 mg/L. Higher concentrations of trovafloxacin were needed to inhibit ciprofloxacin-resistant staphylococci (MIC 90 4 mg/L) but 56% of such strains were inhibited by 1 mg/L of trovafloxacin. Trovafloxacin was four-to 32-fold more active than ciprofloxacin against the streptococci (groups A, B and G, and viridans streptococci) and pneumococci. It was two-to four-fold more active than ciprofloxacin against ciprofloxacin-susceptible Enterococcus faecalis and Enterococcus faecium, and inhibited 50% of ciprofloxacinresistant strains of enterococci at 2 mg/L. Trovafloxacin was the most active agent tested against Listeria monocytogenes and Corynebacterium jeikeium and was also active against Bacillus cereus and 80% of Rhodococcus equi isolates. Of the other agents tested, the activity of sparfloxacin was closest to that of trovafloxacin, with levofloxacin and ofloxacin being intermediate and norfloxacin being the least active.
Discussion
Our results indicate that trovafloxacin has broad antimicrobial activity against most Gram-positive and Gramnegative organisms isolated from febrile cancer patients and are consistent (with minor differences) with those published by other investigators who have examined the activity of trovafloxacin against organisms from various sources.
1-3 Gooding & Jones 1 tested nearly 800 clinical isolates at the University of Iowa hospitals and found that the MIC 90 s of trovafloxacin were generally two-to eightfold greater than those of ciprofloxacin against the family Enterobacteriaceae, but equal to or half those of ofloxacin. Its activity was comparable to or greater than those of ciprofloxacin, ofloxacin and enoxacin against P. aeruginosa, S. maltophilia and the staphylococci. Neu & Chin 2 found that trovafloxacin was, in general, half as active as ciprofloxacin against the Enterobacteriaceae, although against some species the two agents had similar activities. These investigators and Eliopoulos et al. 8 also demonstrated the superior activity of trovafloxacin compared with most quinolones against Gram-positive organisms, including ciprofloxacin-resistant strains. They also demonstrated that trovafloxacin was the most potent agent tested against Leuconostoc and Pediococcus spp.-organisms that are intrinsically resistant to vancomycin.
Numerous clinical applications have been found for the newer quinolones in neutropenic cancer patients. Agents such as ciprofloxacin, norfloxacin and ofloxacin are used in most large cancer treatment centres for antimicrobial prophylaxis in high-risk patients with prolonged neutropenia, including patients with acute leukaemia undergoing remission induction chemotherapy, and recipients of bone marrow transplantation. 6, 9, 10 Ciprofloxacin and ofloxacin have also been used for the treatment of febrile episodes in neutropenic patients (generally in combination with agents such as the aminoglycosides, -lactams, and vancomycin) both in the hospital and in ambulatory settings. 5, [11] [12] [13] [14] [15] Of the currently available quinolones, ciprofloxacin is the most active, particularly against Gram-negative bacilli including P. aeruginosa, and any newer agents in this class need to be compared with it. None of the currently available Our data indicate that trovafloxacin is comparable to ciprofloxacin against most Gramnegative isolates from our patients. It has, however, substantially better activity against S. maltophilia, which has become an important nosocomial pathogen (this is the fifth commonest Gram-negative species isolated at our institution) and is frequently multi-drug resistant. 16 In addition, its activity against Gram-positive organisms, including many that are resistant to vancomycin, may represent a substantial advantage over currently available quinolones. Toxicity and protection studies of trovafloxacin in animals have indicated a favourable toxicity profile, and efficacy equal to that of ciprofloxacin in treating animal infections. Clinical trials are underway. If proven to be safe and effective, trovafloxacin should be of considerable interest to clinicians in many situations, including the prevention and/or treatment of infections in cancer patients. a Only ranges shown when fewer than ten isolates of any species were tested.
